SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Siyata Mobile, Inc. engages in the provision of cellular communications systems for enterprise customers. It specializes in connected vehicle products for professional fleets, marketed under the Uniden Cellular and Siyata brands. The firm operates through the following geographical segments: Europe, the Middle East and Africa; Unites States; Canada; and Australia and New Zealand. The company was founded by Marc Seelenfreund on October 15, 1986 and is headquartered in Montreal, Canada.

Core AI Holdings Inc.

Core AI Holdings, Inc.

Core AI Holdings ($CHAI) is trending due to the finalization of its merger with Core Gaming, alongside a reverse stock split and ticker change, leading to confusion and volatility. The community is actively discussing the stock's halted trading, the impact of the merger and reverse split on share value, and platform display issues, while also speculating about potential short squeezes and long-term prospects in the AI gaming sector. With a relatively small float, many are closely watching for any news or PR from management to better understand the bull case.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending amid speculation of a potential partnership with Tesla ($TSLA) following a teaser video, driving significant trading volume and a surge in call options. The community is actively discussing the possibility of a collaboration, while also weighing the company's fundamentals and upcoming milestones, regardless of any Tesla deal. Some traders are expressing caution, noting the risk of a pullback if the Tesla rumors prove false.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to a significant surge following positive trial results and the FDA granting Breakthrough Therapy Designation for its Sanfilippo syndrome type B treatment. Community discussions revolve around the potential for continued upward momentum, comparisons to other high-flying stocks, and the possibility of a substantial correction. Some traders are eyeing similar setups in other low-float biotech companies, while others caution against chasing the rally.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is experiencing increased attention as investors analyze the implications of its new Ads Manager for small businesses and a partnership with India's UPI. The community is speculating about potential analyst upgrades and the significance of connecting with India's expanding digital economy. Some traders are noting technical patterns, such as a rounded bottom, suggesting a possible breakout.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

GLTO is experiencing significant interest and volatility, with community members discussing potential halts and price targets, possibly fueled by momentum similar to other recent runners. The stock's low float and potential for a squeeze are key discussion points, with some comparing it to previous high-flying stocks. Chatter also mentions potential news or catalysts that could be driving the price action, though nothing is confirmed.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin ($APP) is trending due to reports of an SEC probe into its data collection practices, sparking concerns about potential regulatory violations. The community is debating the severity of the probe, with some viewing it as a buying opportunity while others anticipate further downside. This news follows a period of significant growth for AppLovin, adding to the intensity of the discussion.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DKNG is trending downwards amid concerns about increased competition from prediction markets like Kalshi and Robinhood, which are impacting investor sentiment. The community is debating the long-term effects of these platforms and whether DraftKings can adapt and maintain its market share. Some investors are calling for stronger leadership and communication from the CEO to address these challenges and instill confidence.

Trilogy Metals, Inc. engages in the development and exploration of mineral properties. The firm holds interests in the Upper Kobuk mineral projects that include the Arctic, a copper-zinc-lead-gold-silver and Bornite, a carbonate-hosted copper projects, which is located in the Ambler mining district in Northwest Alaska. The company was founded on April 27, 2011 and is headquartered in Vancouver, Canada.

Trilogy Metals Inc

TMQ is trending following news that the U.S. government will take a 10% stake in the company to support mining exploration in Alaska. The community is discussing the potential for a short squeeze and the stock's potential to reach double digits, while some express caution about a possible sell-off or secondary offering. The move aligns with broader efforts to secure domestic mineral resources.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell is trending due to strong AI server demand, leading to raised revenue growth expectations and positive community sentiment around its potential. Discussions highlight Dell's increased financial outlook, with some anticipating further price appreciation amid the AI infrastructure buildout. Community members are actively debating entry points and long-term potential given the company's positioning in the AI sector.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the stock approaches its 52-week high, fueled by speculation around government partnerships and potential short squeezes. Community members are actively discussing cup and handle formations, awaiting news catalysts, and comparing TMC's potential to other deep sea mining and critical mineral stocks. The overall sentiment is bullish, with many anticipating a significant price increase upon positive developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$KAPA  I sure would like to know what a legit oncology ace such as @telomerase thinks of Kairos.

Bill Walker

StockTwits Web

Kairos Pharma Ltd.

  I sure would like to know what a legit oncology ace such as 

Mr. X

@Shane_Drinion unfortunately I&#39;m not an &quot;ace&quot;... you have to shoot down five enemy cancer indications before they let you paint your pipette tips red ;) 
 
I didn&#39;t know Kairos existed... their antibody that&#39;s in Phase 2 sounds plausible. I&#39;ll look at them... I&#39;ve never seen a biotech where the CFO was paid $14,660 dollars before. Wonder if he lives under the same bridge as myself?

 unfortunately I'm not an "ace"... you have to shoot down five enemy cancer indications before they let you paint your pipette tips red ;) 
 
I didn't know Kairos existed... their antibody that's in Phase 2 sounds plausible. I'll look at them... I've never seen a biotech where the CFO was paid $14,660 dollars before. Wonder if he lives under the same bridge as myself?

@Shane_Drinion well they&#39;re certainly lean and mean, they make MAIA Biotechnology look fat and overfunded ;) 
 
The MOA for the lead asset looks plausible and the lead trial has good interim results. My quibble would be that long term NO ONE is going to put up with chemical castration as a prostate-cancer treatment because of the side effects, so making an antibody to make it possible to keep chemical castration effective longer will not always be salable (will be replaced by e.g. CADL&#39;s immunotherapy).  
 
Right now it would still be a viable product, unfortunately.

 well they're certainly lean and mean, they make MAIA Biotechnology look fat and overfunded ;) 
 
The MOA for the lead asset looks plausible and the lead trial has good interim results. My quibble would be that long term NO ONE is going to put up with chemical castration as a prostate-cancer treatment because of the side effects, so making an antibody to make it possible to keep chemical castration effective longer will not always be salable (will be replaced by e.g. CADL's immunotherapy).  
 
Right now it would still be a viable product, unfortunately.

@telomerase Your input is much appreciated. Thank you.

 Your input is much appreciated. Thank you.